Vietnam Mandates VN-EMR Interoperability for Imported Diagnostic Devices from Aug 2026

On May 10, 2026, Vietnam’s Ministry of Industry and Trade (MOIT), jointly with the Ministry of Health, issued Circular No. 22/2026/TT-BCT, requiring all imported medical diagnostic devices—including ultrasound systems, digital radiography (DR) units, and endoscopy systems—to be pre-installed with a VN-EMR v3.2–compliant interoperability module starting August 1, 2026. This regulation directly impacts medical device exporters, firmware developers, certification service providers, and distributors operating in or supplying to the Vietnamese market.

Event Overview

On May 10, 2026, MOIT and the Ministry of Health jointly signed and published Circular No. 22/2026/TT-BCT. The circular stipulates that, effective August 1, 2026, all imported diagnostic equipment must ship with a built-in API interface module conforming to the Vietnam National Electronic Medical Record standard (VN-EMR v3.2) and must pass interoperability testing conducted by VINA-CEM, Vietnam’s locally authorized certification body. The requirement applies to the full scope of diagnostic equipment categories. Exporters—particularly those based in China—are advised to allocate at least three months for firmware development and local certification preparation.

Which Subsectors Are Affected

Direct Exporters (e.g., Chinese OEMs and ODMs)

These enterprises supply diagnostic devices to Vietnam under their own brand or as private-label manufacturers. They are directly responsible for ensuring hardware-software compliance before shipment. Impact arises from mandatory firmware integration, version control, and post-deployment validation—potentially delaying time-to-market and increasing engineering overhead.

Firmware and Software Development Providers

Vendors specializing in embedded medical software, DICOM integration, or EMR connectivity modules face increased demand for VN-EMR v3.2–specific adaptations. Impact includes tighter deadlines for module customization, documentation alignment with VINA-CEM test protocols, and traceability requirements for regulatory audit trails.

Certification and Conformity Assessment Service Providers

Third-party labs and consultants offering CE, ISO 13485, or local registration support must now expand capabilities to include VN-EMR interoperability verification. Impact manifests as new service line development, staff training on VN-EMR v3.2 technical annexes, and coordination with VINA-CEM’s evolving test procedures.

Distributors and Regulatory Agents in Vietnam

Local importers and regulatory representatives act as the formal applicants for device registration. They bear responsibility for submitting firmware validation reports and test certificates. Impact includes heightened due diligence on supplier readiness, added contractual clauses regarding compliance warranties, and potential liability exposure if non-compliant units enter customs clearance.

What Relevant Enterprises or Practitioners Should Monitor and Do Now

Track official VN-EMR v3.2 implementation guidance and VINA-CEM test criteria updates

The circular references VN-EMR v3.2 but does not publish its full technical annexes or test case library. Analysis shows that final conformance will depend on documents yet to be released by Vietnam’s eHealth Authority. Enterprises should subscribe to VINA-CEM’s public notifications and monitor MOIT’s official portal for supplementary technical notices.

Confirm device classification against the official ‘Diagnostic Equip’ scope list

The regulation applies broadly to diagnostic equipment—but precise inclusion criteria (e.g., whether portable ultrasound or AI-enabled analysis modules fall under scope) remain undefined in the circular. Observation shows that MOIT may issue interpretive notes ahead of the August 2026 enforcement date. Exporters should cross-check current HS codes and product descriptions against Vietnam’s latest Medical Device Classification List (2025 revision).

Distinguish between policy signal and operational readiness

This is a regulatory mandate—not a recommendation. However, enforcement capacity (e.g., customs inspection protocols, real-time firmware verification at ports) remains unconfirmed. From industry perspective, early adopters who complete VINA-CEM testing by Q3 2026 may benefit from priority customs handling or pre-clearance facilitation—though no such mechanism has been formally announced.

Initiate internal firmware roadmap planning and supplier alignment now

Given the stated 3-month minimum timeline for firmware development and certification, enterprises should map existing device families against VN-EMR v3.2 API requirements, identify legacy platforms needing rework, and initiate technical dialogue with VINA-CEM–accredited labs. Delaying this until mid-2026 risks missing the August deadline, especially for devices requiring hardware-level secure boot or cryptographic signature updates.

Editor Perspective / Industry Observation

This circular signals Vietnam’s strategic shift toward health data sovereignty and system-level integration—not just device-level safety. Observably, it mirrors broader ASEAN trends where national EMR standards increasingly serve as de facto market access gates. Analysis shows that while the rule takes effect in August 2026, its real impact lies in accelerating consolidation among smaller exporters unable to absorb certification costs or firmware engineering cycles. It is currently more of an operational inflection point than a standalone compliance hurdle: success depends less on passing one test and more on embedding interoperability into R&D and quality management systems long-term.

Conclusion

This regulation marks a structural tightening of Vietnam’s medical device market entry framework—centered on data exchange capability rather than physical performance alone. It does not represent an isolated administrative update but reflects an intentional alignment of import controls with national digital health infrastructure goals. Currently, it is best understood as a binding technical gateway requiring proactive, cross-functional preparation—not a distant policy risk to be monitored passively.

Source Attribution

Main source: Vietnam Ministry of Industry and Trade (MOIT) and Ministry of Health Joint Circular No. 22/2026/TT-BCT, issued May 10, 2026.
Points requiring ongoing observation: VN-EMR v3.2 technical annexes, VINA-CEM’s official test protocol release schedule, and any MOIT-issued clarifications on device scope interpretation prior to August 1, 2026.